2019 Vancomycin-Resistant Enterococcus faecium Infections R&D Pipeline Drugs, Companies, Trials and Developments
The global demand for Vancomycin-Resistant Enterococcus faecium Infections treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Vancomycin-Resistant Enterococcus faecium Infections are driving leading companies to invest their resources on the pipeline.
Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Vancomycin-Resistant Enterococcus faecium Infections pipeline companies from advancing their products.
Vancomycin-Resistant Enterococcus faecium Infections Report Description
The H1-2019 pipeline review report on Vancomycin-Resistant Enterococcus faecium Infections is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Vancomycin-Resistant Enterococcus faecium Infections pipeline guide presents information on all active drugs currently being developed for Vancomycin-Resistant Enterococcus faecium Infections. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Vancomycin-Resistant Enterococcus faecium Infections pipeline candidate are analyzed.
Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Vancomycin-Resistant Enterococcus faecium Infections drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Vancomycin-Resistant Enterococcus faecium Infections product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Vancomycin-Resistant Enterococcus faecium Infections pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Vancomycin-Resistant Enterococcus faecium Infections pipeline report includes-
Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Vancomycin-Resistant Enterococcus faecium Infections pipeline companies from advancing their products.
Vancomycin-Resistant Enterococcus faecium Infections Report Description
The H1-2019 pipeline review report on Vancomycin-Resistant Enterococcus faecium Infections is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Vancomycin-Resistant Enterococcus faecium Infections pipeline guide presents information on all active drugs currently being developed for Vancomycin-Resistant Enterococcus faecium Infections. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Vancomycin-Resistant Enterococcus faecium Infections pipeline candidate are analyzed.
Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Vancomycin-Resistant Enterococcus faecium Infections drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Vancomycin-Resistant Enterococcus faecium Infections product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Vancomycin-Resistant Enterococcus faecium Infections pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Vancomycin-Resistant Enterococcus faecium Infections pipeline report includes-
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Vancomycin-Resistant Enterococcus faecium Infections pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Vancomycin-Resistant Enterococcus faecium Infections pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Vancomycin-Resistant Enterococcus faecium Infections pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
GLOBAL VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE OVERVIEW
Key Findings, 2019
Disease Overview
Report Guide and Research Methodology
EXECUTIVE SUMMARY
Vancomycin-Resistant Enterococcus faecium Infections Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Vancomycin-Resistant Enterococcus faecium Infections pipeline, H1@2019
Mechanism of Action wise Vancomycin-Resistant Enterococcus faecium Infections Pipeline Candidates
ACURX PHARMACEUTICALS LLC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ALCHEMIA LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
APHIOS CORP VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ARIETIS CORP VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
AZURRX BIOPHARMA INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
C3J THERAPEUTICS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
FERRING INTERNATIONAL CENTER SA VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
HELIX BIOMEDIX INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
HSIRI THERAPEUTICS LLC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
KARVEEL PHARMACEUTICALS VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
LEGOCHEM BIOSCIENCES INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
MGB BIOPHARMA LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
MICURX PHARMACEUTICALS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
NAICONS SRL VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
NOVOBIOTIC PHARMACEUTICALS VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
OPAL BIOSCIENCES LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ORAGENICS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
OVENSA INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ROIVANT SCIENCES VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
SEALIFE PHARMA GMBH VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
SINSA LABS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
WOCKHARDT LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
LATEST VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS DRUG PIPELINE DEVELOPMENTS, 2019
APPENDIX
About Us
Sources and Methodology
Contact Information
Key Findings, 2019
Disease Overview
Report Guide and Research Methodology
EXECUTIVE SUMMARY
Vancomycin-Resistant Enterococcus faecium Infections Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Vancomycin-Resistant Enterococcus faecium Infections pipeline, H1@2019
Mechanism of Action wise Vancomycin-Resistant Enterococcus faecium Infections Pipeline Candidates
ACURX PHARMACEUTICALS LLC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ALCHEMIA LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
APHIOS CORP VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ARIETIS CORP VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
AZURRX BIOPHARMA INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
C3J THERAPEUTICS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
FERRING INTERNATIONAL CENTER SA VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
HELIX BIOMEDIX INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
HSIRI THERAPEUTICS LLC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
KARVEEL PHARMACEUTICALS VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
LEGOCHEM BIOSCIENCES INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
MGB BIOPHARMA LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
MICURX PHARMACEUTICALS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
NAICONS SRL VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
NOVOBIOTIC PHARMACEUTICALS VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
OPAL BIOSCIENCES LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ORAGENICS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
OVENSA INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ROIVANT SCIENCES VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
SEALIFE PHARMA GMBH VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
SINSA LABS INC VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
WOCKHARDT LTD VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
LATEST VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS DRUG PIPELINE DEVELOPMENTS, 2019
APPENDIX
About Us
Sources and Methodology
Contact Information
